# Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) 

Source: https://onco.cc/trials/nct05271318/  
OnCo record `nct05271318` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Pegylated liposomal doxorubicin in ovarian cancer, run by TILT Biotherapeutics Ltd., active and no longer recruiting.

## Summary

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. is a phase 1/2 interventional study registered as NCT05271318 by TILT Biotherapeutics Ltd., with 29 participants planned, started 2022-05-17 and due to reach its primary completion in 2027-03. Interventions recorded: TILT-123, pembrolizumab, pegylated liposomal doxorubicin. Conditions listed: Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05271318
- Phase: 1/2
- Setting: A Two-part, Phase I/Ib, Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase I Part) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase Ib Part) in Patients With Platinum Resistant or Refractory Ovarian Cancer
- Sponsor: TILT Biotherapeutics Ltd.
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT05271318: https://clinicaltrials.gov/study/NCT05271318

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [TILT-123](https://onco.cc/drugs/tilt-123/)

---
JSON: https://onco.cc/api/v1/entities/nct05271318.json